NICE's Lonsurf recommendation marks a step forward for Servier

Final guidance from the UK's National Institute for Health and Care Excellence (NICE) has recommended Lonsurf (trifluridine/tipiracil), within its marketing authorisation, as an option for treating metastatic colorectal cancer, in adults who have had previous treatment.

This drug, which is marketed by independent French drugmaker Servier, should be prescribed with available therapies including fluoropyrimidine, oxaliplatin or irinotecan-based chemotherapies, anti-vascular endothelial growth factor (VEGF) agents and anti-epidermal growth factor receptor (EGFR) agents, or when these therapies are not suitable, the NICE recommendation adds.

Servier has agreed to provide the treatment at a confidential discounted price to the National Health Service (NHS).